Biotech News

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

Zimmer Biomet (ZBH)Zimmer Biomet2026-07-13 12:14 ESTEarnings

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

, /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its second quarter earnings conference call will be webcast on Wednesday, August 5, 2026 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET.

A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . It will be available for replay following the conference call.

Individuals in the U.S. and Canada who wish to dial into the conference call may do so by dialing (800) 330-6710 and using conference ID 7090861. International callers should dial +1 (213) 279-1505 and use conference ID 7090861.

About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet .

View original content to download multimedia: https://www.prnewswire.com/news-releases/zimmer-biomet-announces-webcast-and-conference-call-of-second-quarter-2026-financial-results-302823400.html

SOURCE Zimmer Biomet Holdings, Inc.

Open original release

Related news

ENSCEnsysce Biosciences2026-07-14 12:00 EST

Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant

IKTInhibikase Therapeutics2026-07-14 12:00 EST

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

PMNProMIS Neurosciences2026-07-14 12:00 EST

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

IRWDIronwood Pharmaceuticals2026-07-14 11:30 EST

Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients

SPROSpero Therapeutics2026-07-14 11:02 EST

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

BEATHeartBeam2026-07-14 11:00 EST

HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device

HLFHerbalife Nutrition2026-07-13 18:59 EST

Herbalife Named to TIME's List of America’s Best Companies 2026

ARTLArtelo Biosciences2026-07-13 13:02 EST

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

ENLVEnlivex Therapeutics2026-07-13 13:00 EST

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

EWTXEdgewise Therapeutics2026-07-13 12:42 EST

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

Zimmer Biomet

Zimmer Biomet is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

Stock data

Close
91.34 USD
Market cap
17.67B USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States